Mr. Neil Klompas - 19 Dec 2025 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Reporting relationship: Director
Issuer ticker: INM
Reported as of: 19 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Dec 2025, 11:42:16 UTC
Prior SEC filing: 21 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Eric A Adams, attorney-in-fact for Mr. Neil Klompas

Key filing fact

Mr. Neil Klompas filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 19 Dec 2025.

Key facts

This page summarizes Mr. Neil Klompas's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Dec 2025, 11:42.

Change

Previous filing in this sequence was filed on 21 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001761857 Primary reporting owner

Klompas Neil A

Relationship: Director
Address: 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER, BRITISH COLUMBIA, CANADA
Signature: /s/ Eric A Adams, attorney-in-fact for Mr. Neil Klompas
Signature date: 19 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INM transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,750
Change %: +50%
Price: $0.000000
Shares after: 5,250
Date: 19 Dec 2025
Ownership: Direct
Underlying class: Common shares
Underlying amount: 1,750
Exercise price: $1.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner.